Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences (NASDAQ: ANIX) announced FDA approval of an individual patient IND for a second dose of its ovarian cancer CAR-T therapy. This follows encouraging findings in a patient from the lowest dose cohort, including tumor necrosis, inflammation, and T cell infiltration. The patient has remained off new therapy for months with no new disease, and her tumor marker began to fall after initial elevation.
The Phase I clinical trial at Moffitt Cancer Center is treating recurrent ovarian cancer patients who have failed standard therapies. Six patients have been treated so far in two cohorts. Dr. Robert Wenham, principal investigator, expressed optimism about the potential for increased response with successive dosing. Anixa's CEO, Dr. Amit Kumar, noted surprise and encouragement at seeing a notable response at such a low initial dose.
Anixa Biosciences (NASDAQ: ANIX) announced that its collaborator, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for a patent application on breast cancer vaccine technology. This extends the patent protection to Japan, in addition to existing U.S. and European patents. Anixa is the exclusive worldwide licensee of this technology.
The vaccine, currently in phase one clinical trials at Cleveland Clinic, targets α-lactalbumin, a breast-specific lactation protein present in certain breast cancers but not in normal aging tissues post-lactation. By activating the immune system against this 'retired' protein, the vaccine aims to provide preemptive protection against emerging breast tumors expressing α-lactalbumin.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company focused on cancer treatment and prevention, has announced a $5 million share repurchase program. The program, authorized by the Board of Directors, allows for the repurchase of outstanding common stock over a 12-month period. Dr. Amit Kumar, Chairman and CEO, stated that this decision reflects confidence in the company's future outlook, balance sheet strength, and clinical development pipeline. He also expressed the belief that Anixa's stock is currently undervalued.
The repurchases will be made through open-market transactions in compliance with securities laws. The program can be suspended or discontinued at any time, and no shares have been repurchased to date. This initiative aims to enhance long-term shareholder value.
Anixa Biosciences has treated the sixth and final patient in the second dosage cohort of its Phase 1 clinical trial for an ovarian cancer CAR-T therapy, partnered with Moffitt Cancer Center. If no adverse effects are observed, the third dosage cohort, with a tenfold increase in dose, may commence next month. The trial focuses on evaluating the safety and efficacy of Anixa's FSHR-targeting CAR-T technology. The first cohort showed no dose-limiting toxicities, and a notable response from one patient was observed despite the subtherapeutic dose. The second cohort, receiving triple the initial dose, also reported no dose-limiting toxicities. The therapy involves intraperitoneal delivery, which potentially minimizes side effects and enhances targeting efficacy.
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor (FSHR), which is uniquely expressed on ovarian cells. Safety was confirmed in the first cohort of three patients, and the second cohort, including the fifth patient, receives triple the dose of engineered T-cells. According to Dr. Amit Kumar, Anixa's Chairman and CEO, the trial continues to show that the therapy is safe and well-tolerated, offering hope for an effective CAR-T treatment for solid tumors.
Anixa Biosciences, a clinical-stage biotechnology company, announced an expanded partnership with Cleveland Clinic to develop novel cancer vaccines targeting various cancer types. The vaccines focus on a unique scientific approach by immunizing against 'retired' proteins found in cancer cells, aiming to destroy cancer cells as they arise and prevent tumor formation. Collaborating on breast cancer and ovarian cancer vaccines, the partnership aims to lead in cancer research with promising preliminary data.
Anixa Biosciences, Inc. CEO Dr. Amit Kumar was featured on the 'Target: Cancer Podcast' by oncologist Dr. Sanjay Juneja, discussing 'The Vaccine That Could End Breast Cancer.' The podcast highlighted Anixa's unique vaccine technology aiming to prevent the growth and spread of cancer cells. Dr. Juneja praised the potential impact of Anixa's vaccines on cancer treatment.
Anixa Biosciences, a clinical-stage biotechnology company, will participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024. The CEO will present the company's cancer treatment and prevention programs, including a breast cancer vaccine in Phase 1 trials and a CAR-T cell therapy for ovarian cancer in Phase 1 trials. The company has a capital efficient business model with strong positive data and no debt.
FAQ
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
